Lonza expands its HPAPI production capacity at its Switzerland facility after entering an agreement with AstraZeneca, and invests in manufacturing to establish efficiency.
The Access to Medicines Foundation has launched a ‘benchmark’ that maps drug industry efforts to stem the spread of drug resistance at the World Economic Forum in Davos, Switzerland.
“Small molecule products should be packaged at the location where they are produced,” says Roche, which is laying-off 235 jobs at a packaging plant in Switzerland.
AMRI has been hired by the NIH to provide synthesis and manufacturing services for APIs being developed by the National Center for Advancing Translational Sciences (NCATS) division of preclinical innovation.
Drug companies were a more important source of revenue for Lonza in 2015 than in previous years with four of its five biggest spending customers coming from the pharmaceutical sector.
Government purchasing commitments would discourage industry antibiotic marketing and help developers overcome reluctance to invest in new antimicrobials say drugmakers in Davos.
The increase in dodgy erectile dysfunction drugs seized in Switzerland does not mean the country is a weak point for counterfeiters shipping to Europe according to Swissmedic.
Biopharma outsourcing growth has helped to boost the bottom line of Lonza, the world’s largest manufacturer of drug ingredients, though a topsy-turvy Swiss franc has caused the company to hold off on making any projections for 2015.
Manufacturing powerhouse Roche is doubling down on its small molecule manufacturing with investments of $134.6m in two facilities in Basel, Switzerland.
Novartis has confirmed that pharma jobs will be reallocated in 2014 in a continuation of the productivity drive that saved the firm $2.8bn (EUR2bn) last year.
Lonza says its pharmaceutical business ‘performed as expected’ in the third quarter and that its restructuring efforts – which have seen it cut nearly 800 jobs– are on track to deliver productivity gains.
Lonza says it will cut jobs at its facility in Visp, Switzerland and that it may enact ‘similar productivity improvement programmes’ at other facilities.
Lonza has brought in a new exec to oversee cost reduction and efficiency efforts at its largest custom API manufacturing plant in what CEO Richard Ridinger calls the Visp challenge.
Synergy Health has completed a $62.9m (€47.6m) takeover of Swiss sterilisation firm Leoni Studer Hard from Leoni Group in a bid to further its reach in Europe.
Patheon’s European HQ is up and running to help manage the firm’s growing European operations, specifically its development and commercial service offerings provided by units in France, Italy and the UK.
Lonza of Switzerland is reaping the benefit of a shift away from bulk chemicals and towards custom manufacturing of high-value pharmaceuticals with a 13 per cent hike in sales in the first half of the year.
German speciality chemicals firm CABB has scooped up Swiss company
SF-Chem in a deal set to create a leading European supplier of
chlorine and speciality intermediates.
Johnson Matthey, a British catalyst, precious metals and chemicals
firm with a division that provides contract manufacturing services
of active pharmaceutical ingredients (APIs) to pharmaceutical
companies, has bought chemical technology...
Munich-based Sud-Chemie is set to expand its pharmaceutical
packaging business to German-speaking markets with a joint venture
with Swiss company Plaspaq SA.
Drug companies are to trial a unique form of brand protection by
incorporating a laser marking system on glass vials, which is hoped
to act as a deterrent to counterfeiters as engraving is impossible
to remove and difficult to copy.
Pharmaceutical company Novartis has started building a pilot plant
at its Stein site near Basel in Switzerland to supply sterile
dosage forms for clinical trials.
Schweizerhall is well on the way to completing its acquisition of
Cimex Pharma, and as a result completing the first stage of its
transition to become a specialist supplier to the European generics
industry, reports Phil Taylor.
Switzerland's Novartis has confirmed that it is interested in
joining with Aventis, but will not proceed with a formal bid unless
the French government draws back from its hostile stance on a
link-up, reports Phil Taylor.
The French government has embarked on a fact-finding exercise to
try to work out ways it can address the country's diminishing
standing as a centre for biopharmaceutical R&D.
Switzerland's Novartis has confirmed that it is in discussions with
Aventis which could lead to a counter-offer to fend off the hostile
takeover bid from France's Sanofi-Synthelabo.
Patheon Italia has extended its manufacturing services agreement
with Roche to continue to supply the Swiss firm with solid, liquid
and sterile products for the European market.
Shareholders at Swiss pharmaceutical company Roche welcomed the
start of a new era as the company summarised recent events,
including the divestment of the vitamins business, at its annual
general meeting yesterday.
